VivoSeq
Other

Central Nervous System Disease

2

Pipeline Programs↗

1

Active Trials↗

1

Companies Involved↗

Central Nervous System Disease is an early-stage landscape with 2 programs across 1 company. The most active players are Eli Lilly.

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eli Lilly logo

Eli Lilly

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical
No programs
Phase 11

Enzastaurin

Eli Lilly

Phase 21

SDZ MSL-109

National Center for Research Resources (NCRR)

Phase 3
No programs
Approved
No programs

Analysis

Trial Status

2

clinical trials

Completed1 · 50%
Recruiting1 · 50%

Clinical Trials

Trial Activity

Phase I/II Study of Human Anti-Cytomegalovirus (CMV) Monoclonal Antibody MSL-109 in Newborns With Symptomatic Congenital CMV Infection Without Central Nervous System Disease
Completed·NNational Center for Research Resources (NCRR)·Phase 1/2·NCT00004642
Comprehensive Multimodal Analysis of Patients With Neuroimmunological Diseases of the CNS
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00794352·2,400 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)